Teva Active Pharmaceutical Ingredients
Teva Pharmaceutical Industries' international business unit for developing and manufacturing active pharmaceutical ingredients.
Last updated October 14, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Teva Active Pharmaceutical Ingredients (TAPI), also known as Teva API, is the active-pharmaceutical-ingredient business unit of Teva Pharmaceutical Industries. It develops, manufactures, and markets the chemical, biological, and other raw materials used in pharmaceutical products. Although the unit supplies a substantial portion of Teva's internal API requirements, it also operates as a commercial supplier to other pharmaceutical companies in international markets. Its business therefore combines internal vertical integration with third-party contract and merchant sales. TAPI is headquartered in Israel and has developed an international manufacturing, research, and commercial network through organic development and acquisitions. The Israeli Teva-Tech operation, formerly associated with the Asia and Plantex plants, is described as a central part of the division's history and capabilities. Over time, the business expanded its geographic footprint through acquisitions and the integration of API manufacturing and development facilities in Europe, Asia, North America, Latin America, and other international locations. The reference material describes a network of 21 plants and sales offices worldwide, including 15 API production facilities distributed across Israel, Hungary, Italy, the United States, the Czech Republic, India, Mexico, Puerto Rico, Monaco, China, and Croatia. The division's portfolio covers approximately 400 active pharmaceutical ingredients. These serve therapeutic areas including respiratory medicine, cardiovascular treatment, cholesterol management, central nervous system medicines, dermatology, hormones, anti-inflammatory products, oncology, immunosuppressants, and muscle relaxants. TAPI's activities extend beyond routine production: it invests in process development, manufacturing technology, facility upgrades, and methods intended to reduce production costs. Its intellectual-property portfolio has been described as comprising more than 1,200 granted patents and pending applications worldwide, although the precise date of that count is not specified in the available reference material. TAPI's research and development organization includes more than 760 scientists working across seven development centers. The principal centers are in Israel, with capabilities in synthetic products and peptides, and Hungary, with expertise in fermentation and semi-synthetic products. Additional development activities are identified in India, Italy, Croatia, Mexico, and the Czech Republic, including work on high-potency active ingredients. The R&D program addresses intermediates as well as chemical and biological APIs, with applications in generic medicines and Teva's proprietary products. The division's manufacturing expertise includes chemical synthesis, semi-synthetic fermentation, enzymatic synthesis, high-potency manufacturing, plant-extract technology, synthetic peptides, vitamin D derivatives, and prostaglandins. It also applies solid-state and particle-engineering technologies to control characteristics such as particle-size distribution, bulk density, specific surface area, and polymorphism. Its facilities are described as operating in compliance with applicable current Good Manufacturing Practice requirements in the United States, Europe, Japan, and other jurisdictions. Where products involve controlled substances in the United States, the business must also comply with the Controlled Substances Act and regulations administered by the Drug Enforcement Administration. The available reference identifies third-party sales of $724 million in 2014, indicating that TAPI was a substantial external supplier as well as an internal Teva service. No more recent financial figure is supplied here. TAPI's principal competitive proposition is breadth of portfolio, multinational manufacturing capacity, process-development expertise, regulatory familiarity, and its ability to support pharmaceutical customers with both established an…
History
TAPI emerged from Teva Pharmaceutical Industries' long-term development of an internally integrated API capability. The Israeli Teva-Tech operation is identified as a historical core of the division and was formerly associated with the Asia and Plantex plants. Teva-Tech was established in Israel in 1995, while the broader TAPI organization later incorporated a wider collection of acquired and developed sites. Because the available reference does not provide a distinct legal incorporation date for TAPI itself, 1995 should be understood as the foundation date cited for Teva-Tech rather than necessarily the creation date of the present business unit. During the 1990s, Teva expanded its API platform through a series of acquisitions and facilities. The reference lists ProsIntex in Italy in 1991, ICI in Italy and Biogal in Hungary in 1995, BioCraft in Missouri in 1996, PFC in Italy in 2002, RDL in India in 2003, Sicor API operations in Italy, Mexico, and Switzerland in 2004, Wanma in China and Ivax Corporation in 2006, and Archimica in Puerto Rico in April 2008. These transactions broadened TAPI's manufacturing base, geographic reach, and technical capabilities. The expansion accelerated in 2008. Teva acquired Bentley in Spain in July and Barr-Pliva in Croatia in December, according to the reference material. In 2011, it acquired Theramex in Monaco. Collectively, these investments helped create a network spanning Israel, Europe, Asia, North America, Latin America, and other international markets. The reference describes the resulting organization as operating 21 plants and sales offices worldwide, with 15 API production facilities in a range of countries. TAPI's evolution was not solely acquisition-led. The business also invested in new API development, process engineering, production-facility upgrades, and cost-reduction programs. Its research organization grew around specialized centers in Israel, Hungary, India, Italy, Croatia, Mexico, and the Czech Republic. These centers work on synthetic and semi-synthetic chemistry, fermentation, biological processes, peptides, intermediates, and high-potency materials. This structure supports both Teva's generic medicines and its proprietary pharmaceutical products. By the period documented in the reference, TAPI had become both a major internal supplier and an external competitor in global API markets. Its product range covered roughly 400 APIs across numerous therapeutic categories, while its patent portfolio included more than 1,200 granted patents and pending applications. In 2014, third-party sales were reported at $724 million, demonstrating the scale of its merchant business at that time. The reference does not provide later financial results, a current executive roster, or a detailed account of subsequent restructuring. Accordingly, the documented history is strongest for TAPI's formation, acquisition-led internationalization, technology base, and role within Teva's vertically integrated pharmaceutical model.
- 2014
Third-party sales reached $724 million
[1]TAPI's reported sales to third-party customers totaled $724 million for 2014.
- 2011
Theramex acquisition
[1]Teva acquired Theramex in Monaco as part of the international growth of its API business.
- 2008
Archimica acquisition
[1]In April 2008, Teva acquired Archimica in Puerto Rico.
- 2008
Bentley acquisition
[1]In July 2008, Teva acquired Bentley in Spain.
- 2008
Barr-Pliva acquisition
[1]In December 2008, Teva acquired Barr-Pliva in Croatia.
- 2006
Wanma and Ivax expansion
[1]The reference lists acquisitions of Wanma in China and Ivax Corporation, broadening the resources available to Teva's API operations.
- 2004
Sicor API acquisition
[1]Teva acquired Sicor API operations in Italy, Mexico, and Switzerland.
- 2003
RDL acquisition
[1]Teva acquired RDL in India, expanding its API presence in South Asia.
- 2002
PFC acquisition
[1]Teva acquired PFC in Italy.
- 1996
BioCraft acquisition
[1]BioCraft in Missouri, United States, was acquired and became part of the expanding API network.
Products and positioning
An international, vertically integrated API supplier combining broad therapeutic coverage with process-development, high-potency, fermentation, peptide, and multinational manufacturing capabilities.
Active pharmaceutical ingredients
Broad API portfolio
TAPI produces approximately 400 APIs serving therapeutic areas that include respiratory, cardiovascular, cholesterol-management, central nervous system, dermatological, hormonal, anti-inflammatory, oncology, immunosuppressive, and muscle-relaxant medicines. The portfolio supports both Teva's own pharmaceutical products and sales to external pharmaceutical customers.
Specialty API manufacturing
High-potency APIs
TAPI develops and manufactures high-potency active ingredients through specialized development and production capabilities identified in sites including the Czech Republic, India, Mexico, Croatia, and other locations. These materials require specialized containment, handling, process controls, and regulatory compliance.
Peptide APIs
Synthetic peptides
Synthetic peptides are among the technologies associated with TAPI's Israeli research and manufacturing capabilities. The division's peptide work forms part of its broader effort to develop commercially viable processes for technically complex pharmaceutical ingredients.
Biological and fermentation-derived APIs
Fermentation and semi-synthetic APIs
TAPI's Hungarian development center is identified with fermentation and semi-synthetic products. These capabilities complement chemical synthesis and support the production of APIs and intermediates derived from biological or fermentation-based processes.
Specialty pharmaceutical raw materials
Specialty derivatives and extracts
The division's technology base includes vitamin D derivatives, prostaglandins, plant-extract technology, enzymatic synthesis, and solid-state particle engineering. These capabilities allow control over characteristics such as polymorphism, particle-size distribution, bulk density, and surface area.
Brand decisions
2011
Acquisition of TheramexM&ABackground
Teva continued using acquisitions to broaden the geographic reach of its API business.
Action taken
Teva acquired Theramex in Monaco.
Aftermath
Theramex became part of the international set of facilities and operations associated with TAPI.
2008
Three-country acquisition expansionM&ABackground
TAPI expanded its international manufacturing and development network through multiple transactions.
Action taken
Teva acquired Archimica in Puerto Rico, Bentley in Spain, and Barr-Pliva in Croatia during 2008.
Aftermath
The acquisitions increased TAPI's presence in the Caribbean, Western Europe, and Central Europe.
2004
Acquisition of Sicor API operationsM&ABackground
Teva continued to build an international API manufacturing footprint.
Action taken
Teva acquired Sicor API operations in Italy, Mexico, and Switzerland.
Aftermath
The transaction added facilities and capabilities across Europe and the Americas.
1995
Establishment of Teva-TechStrategyBackground
Teva sought to strengthen its Israeli API manufacturing and development capabilities.
Action taken
Teva founded Teva-Tech in Israel.
Aftermath
Teva-Tech became a central operation associated with the later TAPI business.
1991
Acquisition of ProsIntexM&ABackground
Teva was expanding its API manufacturing and development base in Europe.
Action taken
Teva acquired ProsIntex in Italy.
Aftermath
The acquisition became part of the European foundation of Teva's international API network.
Recent events
- 2014
Teva API reported $724 million in third-party sales[1]
Other
The available reference reports that sales by TAPI to external, third-party customers totaled $724 million in 2014. The figure excludes no stated categories and should not be treated as a current financial measure.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/teva-active-pharmaceutical-ingredients · Editorial policy · How profiles are compiled